FDA Grants Emergency Use Authorization for Merck's Bravecto to Treat Screwworm Infestations
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization for Merck & Co.'s (MRK) antiparasitic medication, Bravecto. The authorization allows the chewable tablets to be used in dogs and puppies to treat new infestations of screwworms. Bravecto is already established in the U.S. market as a treatment and preventative measure for various flea and parasite issues. This emergency expansion addresses an immediate veterinary need caused by emerging screwworm threats, potentially broadening the clinical application of Merck's existing antiparasitic portfolio.
Tickers: $MRK
Topics: Antiparasitic Treatment Emergency Use Authorization Veterinary Medicine
Read the full article at Seeking Alpha
Part of the story Merck parasiticide granted FDA emergency use nod for screwworm infestations in dogs (2 articles)